ORENCIA DIN 02402475
Status: Marketed
Holder: BRISTOL-MYERS SQUIBB CANADA
Available to quote
Health Canada record
| Active ingredient(s) | ABATACEPT 125 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L04AA24 ABATACEPT |
|---|
| Original market date | 09-May-2013 |
|---|
| Current status date | 09-May-2013 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ABATACEPT
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02282097 | ORENCIA | BRISTOL-MYERS SQUIBB CANADA | Powder For Solution | ABATACEPT 250 MG | Marketed |
| 02461919 | ORENCIA | BRISTOL-MYERS SQUIBB CANADA | Solution | ABATACEPT 125 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 14146 | 2013-02-21 | Supplement to a New Drug Submission (SNDS) | New formulation for subcutaneous administration |
Request a quote for ORENCIA
How to read a Canadian DIN record